Aquestive Therapeutics Announces Anaphylm Study Results in 8-K

What Happened
Aquestive Therapeutics, Inc. filed a Current Report on Form 8‑K dated August 10, 2026, disclosing results from its human factors validation study and a pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film. The company said these studies were conducted to support its planned resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for treatment of Type 1 allergic reactions, including anaphylaxis. The 8‑K also furnished an investor presentation for meetings with institutional investors and analysts.

Key Details

• Filing date: August 10, 2026 (Form 8‑K).
• Studies announced: human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual film.
• Purpose: results intended to support planned NDA resubmission to the U.S. FDA for Type 1 allergic reactions, including anaphylaxis.
• Exhibits: Press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) dated August 10, 2026; presentation available on the company’s investor website (subject to change).

Why It Matters
These study results are directly tied to Aquestive’s regulatory pathway for Anaphylm; reporting them publicly signals progress toward an NDA resubmission to the FDA. For investors, the announcement is a material clinical/regulatory update — watch for subsequent filings or FDA communications that provide details on timing, data interpretation, or next steps in the review process. The investor presentation may offer additional context for analysts and shareholders assessing the company’s development timeline.